{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"condition":["Lymphoma, Mantle-Cell","Colorectal Cancer","Mantle Cell Lymphoma","Advanced Cancer","Neoplasms"],"disease":["Colorectal Cancer","Mantle Cell Lymphoma","Advanced Cancer","Lymphoma, Mantle-cell","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2213121"],"location":["United States","United Kingdom","France"],"study_start_month":["10"],"keyword":["Ramucirumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents","description":"The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers.","dates":{"creation":"2016-10-15"},"accession":"2213121","cross_references":{"ClinicalTrials___gov":["NCT02745769"],"EU Clinical Trials Register":["2015-004381-28"]}}